Last €62.00 EUR
Change Today -1.89 / -2.96%
Volume 1.3K
ISI On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 12:41 PM 01/28/15 All times are local (Market data is delayed by at least 15 minutes).

isis pharmaceuticals inc (ISI) Snapshot

Open
€64.05
Previous Close
€63.89
Day High
€64.71
Day Low
€61.72
52 Week High
01/26/15 - €65.52
52 Week Low
05/9/14 - €16.27
Market Cap
7.3B
Average Volume 10 Days
528.9
EPS TTM
--
Shares Outstanding
118.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ISIS PHARMACEUTICALS INC (ISI)

isis pharmaceuticals inc (ISI) Related Businessweek News

View More BusinessWeek News

isis pharmaceuticals inc (ISI) Details

Isis Pharmaceuticals, Inc. is engaged in the discovery and development of antisense drugs using novel drug discovery platform. The company’s flagship product includes the KYNAMRO injection, which is an apo-B synthesis inhibitor for patients with homozygous familial hypercholesterolemia; and for the reduction of low-density lipoprotein cholesterol. It also has a pipeline of 31 drugs in development for the treatment of various diseases, including cardiovascular and metabolic diseases; severe and rare diseases, including neurological disorders; and cancer. The company has strategic alliances and collaboration agreements primarily with AstraZeneca AB, Biogen Idec MA Inc., Bristol-Myers Squibb, Eli Lilly and Company, Genzyme Corporation, GlaxoSmithKline, Hoffman-La Roche Inc., F. Hoffmann-La Roche Ltd., Alnylam Pharmaceuticals, Inc., Antisense Therapeutics Limited, Excaliard Pharmaceuticals, Inc., iCo Therapeutics Inc., OncoGenex Technologies Inc., Janssen Biotech, Inc., and Xenon Pharmaceuticals Inc. Isis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.

365 Employees
Last Reported Date: 03/3/14
Founded in 1989

isis pharmaceuticals inc (ISI) Top Compensated Officers

Founder, Executive Chairman, Chief Executive ...
Total Annual Compensation: $1.5M
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $581.4K
Chief Operating Officer, Corporate Secretary,...
Total Annual Compensation: $1.2M
Senior Vice President of Antisense Research
Total Annual Compensation: $631.6K
Senior Vice President of Development
Total Annual Compensation: $624.4K
Compensation as of Fiscal Year 2013.

isis pharmaceuticals inc (ISI) Key Developments

Isis Pharmaceuticals Receives $7 Million for Advancing ISIS-SMN Rx in Children with Spinal Muscular Atrophy

Isis Pharmaceuticals, Inc. announced that it has earned a $7 million milestone payment from Biogen Idec related to the advancement of the ongoing open-label extension study of ISIS-SMNRx in children with spinal muscular atrophy (SMA). The open-label extension study of ISIS-SMNRx is offered to those children with SMA who have completed dosing in Isis' previous studies. In this study, children with SMA are receiving a 12 mg dose of ISIS-SMNRx every six months for the duration of the study.

Isis Pharmaceuticals, Inc. and Alnylam Pharmaceuticals, Inc. Sign New Agreement to Develop RNA Therapeutics

Isis Pharmaceuticals, Inc. and Alnylam Pharmaceuticals, Inc., have signed a new agreement, extending their existing strategic partnership, for the development and commercialization of RNA therapeutics. This new agreement includes a cross-license of intellectual property (IP) on four disease targets, providing each company with exclusive RNA therapeutic license rights for two programs. The agreement also includes a non-exclusive technology IP cross-license, providing each company rights to certain of each other's technology advances for RNA therapeutics through April 2019.

Isis Pharmaceuticals, Inc. and Alnylam Pharmaceuticals Inc. Announce Extension of Strategic Partnership

Isis Pharmaceuticals, Inc. and Alnylam Pharmaceuticals Inc. announced they have formed a new agreement, extending their existing strategic partnership formed originally in 2004 to lead the development and commercialization of RNA therapeutics. This new agreement includes a cross-license of intellectual property (IP) on four disease targets, providing each company with exclusive RNA therapeutic license rights for two programs. The agreement also includes a non-exclusive technology IP cross-license, providing each company rights to certain of each others technology advances for RNA therapeutics through April 2019. Isis and Alnylam lead the RNA-targeted therapeutics space and are innovators in understanding the science and developing the technologies to support RNA-targeted drug discovery. This expansion of license agreement will enable both companies to enhance drug development efforts in particular disease areas while also sharing IP access. The new agreement also includes an extended technology IP cross-license. Specifically, Alnylam is granting Isis a royalty-bearing, non-exclusive license to new platform technology arising from May 2014 through April 2019 for single-stranded antisense therapeutics. In turn, Isis is granting Alnylam a royalty-bearing, non-exclusive license to new platform technology arising from May 2014 through April 2019 for double-stranded RNAi therapeutics. Under the 2004 agreement, Isis licensed to Alnylam its patent estate related to antisense mechanisms and oligonucleotide chemistry for double stranded RNAi drugs in exchange for a technology access fee, participation in fees for Alnylams partnering programs and future milestone and royalty payments from Alnylam for programs that incorporate Isis IP. In turn, Alnylam non-exclusively licensed to Isis Alnylams patent estate relating to antisense motifs and mechanisms and oligonucleotide chemistry to research, develop and commercialize single-stranded antisense therapeutics, ssRNAi therapeutics and to research double-stranded RNAi compounds. Isis also received a license to develop and commercialize double-stranded RNAi drugs targeting a limited number of therapeutic targets on a non-exclusive basis.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ISI:GR €62.00 EUR -1.89

ISI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ACADIA Pharmaceuticals Inc $31.24 USD -0.46
Acorda Therapeutics Inc $42.88 USD -0.82
Depomed Inc $18.90 USD -0.39
Impax Laboratories Inc $38.82 USD -0.08
Regulus Therapeutics Inc $18.09 USD -0.81
View Industry Companies
 

Industry Analysis

ISI

Industry Average

Valuation ISI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 50.1x
Price/Book 24.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 45.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ISIS PHARMACEUTICALS INC, please visit www.isispharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.